ApconiX Welcomes Dr Andreas Hartmann
ApconiX is delighted to welcome Dr Andreas Hartmann who joins the Toxicology and DMPK Consultancy Team as a non-clinical safety specialist and will be working with Dr Richard Knight, Director and co-founder of ApconiX.
Academic Career
Andreas Hartmann lives in Germany, near the Switzerland border. He started his career at the University of Ulm with a PhD in human genetics, studying genetic toxicology and assessing DNA damage on single-cells. He continued his academic career with a post-doc in radiation oncology at the UCSF Medical Center in San Francisco. Andreas then joined Novartis as a Lab Head in genetic toxicology. Over the years he moved on to project toxicology, initially focusing on Neuroscience projects. He then became the Preclinical Safety Therapeutic Area Head in disease areas of Neuroscience, Infections Diseases, Ophthalmology, Musculo-Skeletal Diseases and marketed products. In this role he was leading teams of project toxicologists responsible for non-clinical deliverables from target identification to post-marketing including regulatory submissions for CTAs/INDs and MAAs/NDAs/BLAs for small molecules, biotherapeutics, gene therapy products and oligonucleotides. In addition, he was heading the Impurity Safey team.
Besides his roles at Novartis, Andreas was also active in Industry Associations. In his role as Chair of the EFPIA (European Federation of Pharmaceutical Industries and Associations) Preclinical Development Expert Group (PDEG) he was interacting with regulators worldwide. As part of this role, he was the safety lead of the Nitrosamine Task Force and the co-lead of the Titanium Dioxide Task Force. Finally, he is giving lectures to post-graduate students of the MSc course in Drug Sciences at the University of Basel. Andreas is co-authoring >70 papers and book chapters in the field of non-clinical safety.
Working with ApconiX
Andreas first met Dr Richard Knight and Dr Ruth Roberts, directors and co-founders of ApconiX, when they were working at AstraZeneca, and kept in touch over the years. As a non-clinical safety associate, Andreas’s role will include advising clients’ project teams, delivering the toxicology strategy and assisting with regulatory interactions.
Dr Richard Knight commented: “Andreas is a fantastic addition to the ApconiX team and brings enormous drug safety experience. We are delighted to have him in the group. In Andreas’ time at Novartis he worked with different drug modalities and has particular expertise in the development of neuroscience therapeutics.”
Interests Outside of work
Andreas is very active. He likes travelling with his daughters and is participating in long distance open water swim competitions and triathlons (Olympic distance, covering 1.5km swimming, 40km cycling and 10km running). He is also planning for a half IronMan in 2027, consisting of 2km of swimming, 90km of cycling and 20km running.
